Format

Send to

Choose Destination
See comment in PubMed Commons below
Immunol Today. 2000 Aug;21(8):371-8.

Natural and designer binding sites made by phage display technology.

Author information

  • 1Target Quest BV, a subsidiary of Dyax Corp, PO Box 5800, 6202 AZ Maastricht, The Netherlands. hhoogenboom@targetquest.nl

Abstract

In the past decade, the drive to develop completely human antibodies for human therapy has led to the development of phage display technology. This technology is able to deliver the ultimate in antibody engineering, that is, high-affinity fully human antibodies to any antigen of choice. Here, this application of phage display technology is reviewed, and the many other antibody-engineering avenues this technology offers are highlighted.

PMID:
10916139
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk